Magnus Tobiasson group

Magnus Tobiasson research group is studying biological and clinical aspects of the myelodysplastic syndrome (MDS).

The main focus of the group is to implement new genetic tools in the management of patients with MDS during the transplantation process. Magnus Tobiasson is coordinating the Nordic MDS group study NMDSG14B, which is developing and evaluating individual minimal residual disease (MRD) markers for early detection of relapse after allogeneic stem cell transplantation. The study has generated several spin-off projects e.g. evaluation of MRD on sorted stem and progenitor cells and evaluation of the importance of achieving clonal reduction prior to transplantation. 

Group leader

Magnus Tobiasson

Research group leader
Hellström Lindberg
H7 Department of Medicine, Huddinge

Group members

Carolin Lindholm

PhD Student
Hellström Lindberg
H7 Department of Medicine, Huddinge

Research support

  • Tobias Stiftelsen
  • Strategic research area (SRA) in stem cells and regenerative medicine
  • Region Stockholm (SLL)
  • Centrum för innovativ medicin (CIMED) 

Publications

Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder.
Klimkowska M, Nannya Y, Gran C, Månsson R, Douagi I, Ogawa S, Nahi H, Tobiasson M
Blood 2021 Mar;137(9):1260-1263

Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data.
Sandmann S, de Graaf AO, Tobiasson M, Kosmider O, Abáigar M, Clappier E, Gallì A, van der Reijden BA, Malcovati L, Fenaux P, Díez-Campelo M, Fontenay M, Hellström-Lindberg E, Jansen JH, Dugas M
J Mol Diagn 2021 Mar;23(3):347-357

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E
Nat Med 2020 10;26(10):1549-1556

Myelodysplastic syndromes: moving towards personalized management.
Hellström-Lindberg E, Tobiasson M, Greenberg P
Haematologica 2020 07;105(7):1765-1779

Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.
Tobiasson M, Pandzic T, Cavelier L, Sander B, Wahlin BE
Leuk Lymphoma 2019 12;60(13):3316-3319

Treatment of myelodysplastic syndrome in the era of next-generation sequencing.
Tobiasson M, Kittang AO
J Intern Med 2019 07;286(1):41-62

Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes.
Rydén J, Edgren G, Karimi M, Walldin G, Tobiasson M, Wikman A, Hellström-Lindberg E, Höglund P
Leukemia 2019 02;33(2):522-527

Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM
Oncologist 2018 02;23(2):159-170

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.
Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, Tobiasson M, Jansson M, Douagi I, Moarii M, Saft L, Papaemmanuil E, Jacobsen SEW, Hellström-Lindberg E
Blood 2017 08;130(7):881-890

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.
Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE
Cell Rep 2017 07;20(3):572-585

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, Karimi M, Krjutskov K, Einarsdottir E, Grövdal M, Jansson M, Ben Azenkoud A, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellström-Lindberg E, Ungerstedt J
Oncotarget 2017 Apr;8(17):28812-28825

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E
Oncotarget 2016 Apr;7(16):22103-15

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.
Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E
Blood Cancer J 2014 Mar;4():e189

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.
Tobiasson M, Alyass B, Söderlund S, Birgegård G
Med Oncol 2010 Mar;27(1):105-7